Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

Home/Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

I started an article about carfilzomib last Tuesday this way:  The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib:
“Is Onyx Pharmaceuticals’ new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask.”

Well, you just read my interview with Dr. Michael Kauffman, Chief Medical Officer of Onyx.  What do you think? 

Onyx is pushing hard for approval.  I just received an e-mail from Lori Murray, Director, Corporate Communications and Investor Relations for Onyx Pharmaceuticals with some hopeful news.  Seems the drug could actually be available in as little as one year vs. two if all goes as planned!

This could be great news!  Even if carfilzomib turns out to be equivalent to Velcade—but different enough to work in some refractory patients and vice versa—many of us would be better off. I just see another one, two or three years of hope if this drug works when others don’t.

In this case, competition is a good thing! Onxy is chasing the dollars and business generated by Millennium’s proteasome inhibitor, Velcade.  So far, it looks like it is working.

With so many new drugs and ongoing studies, buying an additional two or three years is huge! By then there will be two or more newer, hopefully safer novel therapy agents ready to try.

Hope! Most “average” or “normal” multiple myeloma patients should have it. Newly diagnosed, younger patients might want to try Arkansas’ Total Therapy—or just mix and match the wide variety of existing myeloma therapies while we all wait for the next “sort of miracle drug” to come along. “Sort of miracle drug?” “Sort of” because these novel therapy drugs aren’t curing us—miracle drugs because they do help some of us live longer, near normal lives.

But what about the others? What about patients who have more aggressive multiple myeloma, often caused by gene deficiencies—or sometimes just bad luck?

At the suggestion of one of my readers, I will be writing a series about these unfortunate patients next week. What therapies are being developed for difficult cases of multiple myeloma? Tune in Monday.

Feel good and keep smiling! Pat